Showing 7601-7610 of 10163 results for "".
- ASDSA Lauds FDA for Safety Communication on Needle-less Deviceshttps://practicaldermatology.com/news/asdsa-lauds-fda-for-safety-communication-on-needle-less-devices/2460952/The American Society for Dermatologic Surgery Association (ASDSA) applauds the U.S. Food and Drug Administration (FDA) for sending out a safety communication regarding needle-less devices, such as hyaluron pens (HA pens) for injection of dermal fillers. ASDSA had earlier
- Janssen Seeks FDA Nod for Stelara in Juvenile PsAhttps://practicaldermatology.com/news/janssen-seeks-fda-nod-for-stelara-in-juvenile-psa/2460949/Janssen is seeking expanded approval of Stelara (ustekinumab) for pediatric patients aged five and older with juvenile psoriatic arthritis (jPsA). The company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA). The filing is
- Safety Concerns Fuel Vaccine Hesitancy in PsO Patients on Biologics, But Data Fail to Show Increased Riskhttps://practicaldermatology.com/news/safety-concerns-fuel-vaccine-hesitancy-in-pso-patients-on-biologics-but-data-fail-to-show-increased-risk/2460947/Safety concerns and concerns about aggravation of their underlying condition are common drivers of COVID-19 vaccine hesitancy among patients with psoriatic disease, results of a new study show. Data come from an analysis of social media posts from patients in the US, UK, France, Germany, and
- Investigational Agents Show Benefit in Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/investigational-agents-show-benefit-in-chronic-spontaneous-urticaria/2460938/Complete control of chronic spontaneous urticaria (CSU) is associated with improvements in key HRQoL measures, such as overall quality of life, sleep interference, activity interference and work impairment, while a marked decline in these improvements to quality of life is seen among patients wit
- New Data for Galderma’s Nemolizumab Show Rapid Onset in Prurigo Nodularis and Atopic Dermatitishttps://practicaldermatology.com/news/new-data-for-galdermas-nemolizumab-show-rapid-onset-in-prurigo-nodularis-and-atopic-dermatitis/2460935/Investigational monoclonal antibody nemolizumab demonstrates rapid onset of action and significant reduction in symptoms for patients with prurigo nodularis (PN) and atopic dermatitis (AD), according to data presented at the virtual 30th EADV congress and reported by
- Cytrellis Secures New Round of Fundinghttps://practicaldermatology.com/news/cytrellis-secures-new-round-of-funding/2460920/Cytrellis has closed a $50 million Series C funding round. The financing was led by D1 Capital Partners and included participation from an additional new investor, Sands Capital, as well as existing institutional investors, ARCH Venture Partners and PFM Health Sciences. Proceeds will be
- NPF Task Force Issues New Guidance on COVID-19 Vaccine Boosters for PsO Patientshttps://practicaldermatology.com/news/npf-task-force-issues-new-guidance-on-covid-19-vaccine-boosters-for-pso-patients/2460911/The Centers for Disease Control and Prevention (CDC) recently released new information on COVID-19 vaccines for moderately to severely immunocompromised people. Since these individuals may be especially vulnerable to COVID-19, due to their increased
- Sun Pharma, Cassiopea Move Ahead with Winlevi Agreementhttps://practicaldermatology.com/news/sun-pharma-cassiopea-move-ahead-with-winlevi-agreement/2460899/Sun Pharma and Cassiopea SpA announced the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the exclusive License and Supply Agreements signed by both companies for Winlevi (clascoterone cream 1%).
- Skyrizi Now Available As A Single 150mg Injection for Adults with Plaque Psoriasishttps://practicaldermatology.com/news/skyrizi-available-as-a-single-150-mg-injection-for-adults-with-plaque-psoriasis/2460884/Skyrizi® (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor from
- Dr. James Q. Del Rosso Named Senior Vice President of Clinical Research and Strategic Development at Advanced Dermatology and Cosmetic Surgeryhttps://practicaldermatology.com/news/dr-james-q-del-rosso-named-senior-vice-president-of-clinical-research-and-strategic-development-at-advanced-dermatology-and-cosmetic-surgery/2460873/James Q. Del Rosso, DO is now Senior Vice President of Clinical Research and Strategic Development at Advanced Dermatology and Cosmetic Surgery (ADCS). Dr. James Del Rosso and Ms. Allison Lynch, Chief Operating Officer of Pathology and Research Divisions, will oversee the company’